Almansa C - Search Results

1

WLB-87848, a Selective σ₁ Receptor Agonist, with an Unusually Positioned NH Group as Positive Ionizable Moiety and Showing Neuroprotective Activity.

Christmann U, Garriga L, Llorente AV, Díaz JL, Pascual R, Bordas M, Dordal A, Porras M, Yeste S, Reinoso RF, Vela JM, Almansa C. Christmann U, et al. Among authors: almansa c. J Med Chem. 2024 Jun 13;67(11):9150-9164. doi: 10.1021/acs.jmedchem.4c00288. Epub 2024 May 16. J Med Chem. 2024. PMID: 38753759

2

Randomized controlled trial of linaclotide in children aged 6-17 years with functional constipation.

Di Lorenzo C, Nurko S, Hyams JS, Rodriguez-Araujo G, Almansa C, Shakhnovich V, Saps M, Simon M. Di Lorenzo C, et al. Among authors: almansa c. J Pediatr Gastroenterol Nutr. 2024 May;78(5):1059-1068. doi: 10.1002/jpn3.12184. Epub 2024 Mar 27. J Pediatr Gastroenterol Nutr. 2024. PMID: 38533633 Clinical Trial.

3

Towards Multitargeted Ligands as Pain Therapeutics: Dual Ligands of the Ca_vα2δ-1 Subunit of Voltage-Gated Calcium Channel and the μ-Opioid Receptor.

Wegert A, Monnee M, de Graaf W, van Holst F, Bolcato G, Díaz JL, Dordal A, Portillo-Salido E, Reinoso RF, Yeste S, Torrens A, Almansa C. Wegert A, et al. Among authors: almansa c. ChemMedChem. 2024 May 17;19(10):e202300473. doi: 10.1002/cmdc.202300473. Epub 2024 Jan 17. ChemMedChem. 2024. PMID: 38230842

4

Discovery of WLB-89462, a New Drug-like and Highly Selective σ₂ Receptor Ligand with Neuroprotective Properties.

Christmann U, Díaz JL, Pascual R, Bordas M, Álvarez I, Monroy X, Porras M, Yeste S, Reinoso RF, Merlos M, Vela JM, Almansa C. Christmann U, et al. Among authors: almansa c. J Med Chem. 2023 Sep 14;66(17):12499-12519. doi: 10.1021/acs.jmedchem.3c01060. Epub 2023 Aug 22. J Med Chem. 2023. PMID: 37607512

5

Bispecific sigma-1 receptor antagonism and mu-opioid receptor partial agonism: WLB-73502, an analgesic with improved efficacy and safety profile compared to strong opioids.

Vidal-Torres A, Fernández-Pastor B, García M, Ayet E, Cabot A, Burgueño J, Monroy X, Aubel B, Codony X, Romero L, Pascual R, Serafini MT, Encina G, Almansa C, Zamanillo D, Merlos M, Vela JM. Vidal-Torres A, et al. Among authors: almansa c. Acta Pharm Sin B. 2023 Jan;13(1):82-99. doi: 10.1016/j.apsb.2022.09.018. Epub 2022 Sep 25. Acta Pharm Sin B. 2023. PMID: 36815042 Free PMC article.

6

Linaclotide Reduced Response Time for Irritable Bowel Syndrome With Constipation Symptoms: Analysis of 4 Randomized Controlled Trials.

Brenner DM, Lacy BE, Ford AC, Bartolini W, Wu J, Shea EP, Bochenek W, Boinpally R, Almansa C. Brenner DM, et al. Among authors: almansa c. Am J Gastroenterol. 2023 May 1;118(5):872-879. doi: 10.14309/ajg.0000000000002064. Epub 2022 Oct 12. Am J Gastroenterol. 2023. PMID: 36227782 Free PMC article.

7

Productivity Loss and Indirect Burden of Cyclic Vomiting Syndrome in the United States.

Song X, Chen YJ, Perry A, Kagan J, Bhandari S, Almansa C, Richmond C, Levinthal DJ, Venkatesan T. Song X, et al. Among authors: almansa c. Gastro Hep Adv. 2022 Jul 21;1(6):954-962. doi: 10.1016/j.gastha.2022.06.017. eCollection 2022. Gastro Hep Adv. 2022. PMID: 39131254 Free PMC article.

8

Health Care Resource Use and Associated Costs of Cyclic Vomiting Syndrome in the United States.

Chen YJ, Song X, Winer I, Smith P, Bhandari S, Almansa C, Richmond C, Venkatesan T, Levinthal DJ. Chen YJ, et al. Among authors: almansa c. Gastro Hep Adv. 2022 Jul 19;1(6):963-973. doi: 10.1016/j.gastha.2022.06.013. eCollection 2022. Gastro Hep Adv. 2022. PMID: 39131242 Free PMC article.

9

The pharmacokinetics of oral trazpiroben (TAK-906) after organic anion transporting polypeptide 1B1/1B3 inhibition: A phase I, randomized study.

Mukker JK, Dukes G, Tolkoff M, Wang L, Almansa C, Huh SY, Nishihara M, Ramsden D, Chen C. Mukker JK, et al. Among authors: almansa c. Clin Transl Sci. 2022 Jun;15(6):1532-1543. doi: 10.1111/cts.13274. Epub 2022 May 5. Clin Transl Sci. 2022. PMID: 35460165 Free PMC article. Clinical Trial.

10

Evaluation of the Pharmacokinetics of Felcisetrag (TAK-954), a 5-HT₄ Receptor Agonist, in the Presence and Absence of Itraconazole, a Potent CYP3A4 Inhibitor.

Chen C, Zhang L, Almansa C, Rosario M, Cwik M, Balani SK, Lock R. Chen C, et al. Among authors: almansa c. Clin Pharmacol Drug Dev. 2022 Feb;11(2):142-149. doi: 10.1002/cpdd.1046. Epub 2022 Jan 6. Clin Pharmacol Drug Dev. 2022. PMID: 34989180 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

85 results

Search Page

Filters